Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial
Matteo Della Porta(University of Milan), Uwe Platzbecker(National Center for Tumor Diseases), Pierre Fenaux(Saint Louis University Hospital), Sophie Dimicoli‐Salazar(Centre Hospitalier Universitaire de Bordeaux), David Valcárcel(Vall d'Hebron Hospital Universitari), Chien‐Chin Lin(National Taiwan University), Veronika Pozharskaya(Bristol-Myers Squibb (United States)), Ing Soo Tiong(The University of Melbourne), Thomas Prébet(Yale University), Andrius Degulys(Vilnius University), Anna Jonášová(Charles University), Jake Shortt(The University of Melbourne), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Jennie Zhang(Bristol-Myers Squibb (United States)), Amer M. Zeidan(Yale Cancer Center), Yinzhi Lai(Bristol-Myers Squibb (United States)), Richard Pilot(Bristol-Myers Squibb (United States)), Karen L. Keeperman(Bristol-Myers Squibb (United States)), Thomas Cluzeau(Centre Hospitalier Universitaire de Nice), Valeria Santini(Azienda Ospedaliero-Universitaria Careggi), Jiahui Li(Bristol-Myers Squibb (United States)), Shelonitda Rose(Universidad San Carlos), Stefania Paolini(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Sandra Kreitz(Bristol-Myers Squibb (Switzerland)), Rami S. Komrokji(Moffitt Cancer Center)
Cited by 50
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k